Discuss best practices to tackle opioid abuse and other pharmacological abuse in your practice. Learn about the latest guidelines and recommendations on screening, responsible prescription and disposal of opioids.
Urine drug testing is an effective tool to assess for adherence to opioid therapy, misuse, and abuse. In this activity, esteemed faculty discuss the differences between presumptive (screening) and definitive (confirmatory) urine drug testing, including their advantages and drawbacks and reasons why false positive and false negative results occur.
Providers are under increasing pressure to ensure safe and effective prescribing of chronic opiates in light of the opiate epidemic. When a provider needs to taper a dose or wean a patient off chronic opiates, providers may have a lack of knowledge and comfort on how to do so while minimizing symptoms to the patient. This talk will review the signs and symptoms of withdrawal, who is at risk of withdrawal and medications providers can use to minimize withdrawal symptoms. Participants will also walk away with practical rules and guidelines on how to wean patients off chronic opiates or taper to a lower dose. Finally, the talk will review options for transitioning patients to addiction treatment. Participants will get to practice what they learn through several interactive cases.
The routine use of UDT according to current prescription drug monitoring guidelines allows for a comprehensive assessment of opioid misuse grounded in policy rather than decisions based on individual patient characteristics, decreasing the stigma that can be associated with this type of testing.
Charles Argoff, MD, director of the Comprehensive Pain Center at Albany Medical Center, reviews strategies for mitigating risk for opioid misuse and abuse in patients taking opioids for chronic pain management. Dr. Argoff uses case studies to illustrate how to incorporate risk assessment tools into comprehensive screening for patients in chronic pain before you prescribe opioids, so you can better protect yourself and your patients.
In the U.S., about 15.1 million people have an alcohol use disorder and about 4.8 million misuse opioids. This session focuses on the pharmacotherapy of alcohol and opioid use disorders. The faculty will describe and contrast naltrexone and acamprosate treatments for alcohol use disorder and discuss the use of buprenorphine/naloxone to treat opioid use disorder.
This presentation will provide an overview of existing trends in addictive disorders with an emphasis on screening, brief interventions and referrals to treatment (SBIRT) practices that every primary care provider should practice. A review of FDA-approved medications and evidence-based psychosocial practices will be presented. Finally, special emphasis will be placed on describing office-based tools that can be used to identify and prevent prescription opiate abuse.